Zobrazeno 1 - 10
of 1 222
pro vyhledávání: '"ENGAGER"'
Autor:
Shenxia Xie, Wei Shi, Siliang Duan, Xianing Huang, Aiqun Liu, Xiaoqiong Hou, Xuandong Lin, Dani Zhong, Shuyang Sun, Ziqiang Ding, Xiaomei Yang, Xiaoyuan Chen, Xiaoling Lu
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Background T cell-based immunotherapies are facing great challenges in the recruitment and activation of tumor-specific T cells against solid tumors. Among which, utilizing nanobody (Nb) or nanobodies (Nbs) to construct T cell engager has em
Externí odkaz:
https://doaj.org/article/34819bd0e84d4974b541afced7e0be7f
Autor:
Yi Zhang, Miso Park, Lucy Y. Ghoda, Dandan Zhao, Melissa Valerio, Ebtesam Nafie, Asaul Gonzalez, Kevin Ly, Bea Parcutela, Hyeran Choi, Xubo Gong, Fang Chen, Kaito Harada, Zhenhua Chen, Le Xuan Truong Nguyen, Flavia Pichiorri, Jianjun Chen, Joo Song, Stephen J. Forman, Idoroenyi Amanam, Bin Zhang, Jie Jin, John C. Williams, Guido Marcucci
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-18 (2024)
Abstract Background The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providing an opportunity to t
Externí odkaz:
https://doaj.org/article/81c6c4a1c88f4c5d9d2eee24813cc8c0
Autor:
Bill Liao, Christine Tumanut, Lin Li, Adam Corper, Dilip Challa, Alex Chang, Hydari Begum, Elinaz Farokhi, Catherine Woods, Xiaomin Fan
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Natural killer (NK) cells are key players in human innate immunity. Cell engager antibody formats that recruit and activate NK cells more effectively have emerged as a promising immunotherapy approach to target cancer cells through more effective ant
Externí odkaz:
https://doaj.org/article/cb6b464dfe384eb4832cd56fa7dd2049
Autor:
Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Khan, Takeshi Tsuda, Patrick Chames, Javier Lacadena, Luis Álvarez-Vallina, Laura Sanz
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTT cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor microenvironment, where PD-L1 and TGF-β play a p
Externí odkaz:
https://doaj.org/article/3126feeb469c436b90c0b4d00590133a
Autor:
Gerhard Frey, Ana Paula G. Cugnetti, Haizhen Liu, Charles Xing, Christina Wheeler, Hwai Wen Chang, William J. Boyle, Jay M. Short
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTEpithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been
Externí odkaz:
https://doaj.org/article/7fc31e7a3b674b338e4ac1b2672d0edf
Autor:
Ammelie Svea Boje, Lukas Pekar, Katharina Koep, Britta Lipinski, Brian Rabinovich, Andreas Evers, Carina Lynn Gehlert, Steffen Krohn, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Lars Toleikis, Sven Poetzsch, Matthias Peipp, Stefan Zielonka, Katja Klausz
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTNatural killer (NK) cells emerged as a promising effector population that can be harnessed for anti-tumor therapy. In this work, we constructed NK cell engagers (NKCEs) based on NKp30-targeting single domain antibodies (sdAbs) that redirect t
Externí odkaz:
https://doaj.org/article/dab9f66e27944e228e065c4ff4d03f51
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Targeted antibody-based therapy for oncology represents a highly efficacious approach that has demonstrated robust responses against single tumor-associated antigen (TAA) targets. However, tumor heterogeneity presents a major obstacle for targeting m
Externí odkaz:
https://doaj.org/article/941a04c7e3274db39f3c3fb45a222bd1
Autor:
Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, Yeh Chen, Jennifer Hui‐Chun Ho, Fang‐Yu Lin, Xiao‐Tong Tan, Hung‐Che Chiang, Chiu‐Ching Huang, Chih‑Yen Tu, Der‐Yang Cho, Shao‐Chih Chiu
Publikováno v:
Advanced Science, Vol 11, Iss 41, Pp n/a-n/a (2024)
Abstract Immunotherapy targeting immune checkpoints (ICPs), such as programmed death‐ligand‐1 (PD‐L1), is used as a treatment option for advanced or metastatic non‐small cell lung cancer (NSCLC). However, overall response rate to anti‐PD‐
Externí odkaz:
https://doaj.org/article/7864291b849244c5babdc5d7f746e0bd
Autor:
Lisa A. King, Milon de Jong, Myrthe Veth, David Lutje Hulsik, Parsa Yousefi, Victoria Iglesias-Guimarais, Pauline M. van Helden, Tanja D. de Gruijl, Hans J. van der Vliet
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundVγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the
Externí odkaz:
https://doaj.org/article/3eb04d8fffbe403ba273566ef54bbcbc
Autor:
William H. Robinson, David Fiorentino, Lorinda Chung, Larry W. Moreland, Malavika Deodhar, Mary Beth Harler, Carrie Saulsbery, Rebecca Kunder
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
B-cell depletion therapy (BCDT) has been employed to treat autoimmune disease for ~20 years. Immunoglobulin G1 (IgG1) monoclonal antibodies targeting CD20 and utilizing effector function (eg, antibody-dependent cellular cytotoxicity, complement-depen
Externí odkaz:
https://doaj.org/article/f6ca48ff0e614052bb2506a211f875af